A Third of Uveitis Patients Prescribed Excess Corticosteroids

Pavankumar Kamat

February 19, 2021

A new study published in the journal  Eye  suggests that one-third of patients with uveitis in the UK receive excess systemic corticosteroids (CS), and there is a scope to reduce excess prescribing in a quarter of them.

CS are widely prescribed for the treatment of uveitis and scleritis, but have been linked to poor tolerability and substantial long-term morbidity in patients.

Investigators of the Ocular Inflammation Steroid Toxicity Risk (OSTRICH) study conducted an audit of systemic CS prescribing for uveitis at 11 sites in the UK between November 2018 and March 2019. High-dose CS refers to maintenance >7.5 mg prednisolone for more than three consecutive months; alternatively, more than one course of ≥40 mg oral CS or ≥500 mg intravenous methylprednisolone in the past 12 months.

42.7 per cent of eligible patients were treated with oral or intravenous CS over the past 12 months, 33.7 per cent of whom exceeded the threshold for high-dose CS. Among those prescribed excess CS, 25 per cent of the cases were deemed avoidable and were attributed to either long-term prescribing without considering the evidence for alternative strategies, prescribing error or miscommunication. Furthermore, 68.8 per cent of patients prescribed excess CS also received immunomodulatory therapy in the past 12 months.

"Uveitis remains an area of unmet medical need, where CS may be over-utilised as a means of reducing the risk of sight loss in the absence of a sufficient range of effective therapies," the authors stated. They call for a reduction in CS exposure and also recommend modifying the current guidelines to restrict the use of high-dose CS to a maximum of one course per year.

Leandro L, Beare N, Bhan K, Murray PI, Andrews C, Damato E, Denniston AK, Gupta N, Kumar P, Pradeep A, Quhill F, Ross A, Stylianides A, Sharma SM. Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye (Lond). 2021 Feb 02 [Epub ahead of print]. doi: 10.1038/s41433-020-01336-6. doi: 10.1016/j.ophtha.2010.03.029. PMID: 33531696 View full text

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: